Difference between revisions of "POLYCYSTIC KIDNEY DISEASE-TOLVAPTAN"

Latest revision as of 20:03, 13 March 2023

SUMMARY

1. Blocks V2 receptors in distal nephron and collection duct. In PCKD: reduce cysts formation.

2. Prevents the binding of vasopressin, reduce expression of aquaporins.

3. Promotes water excretion: polyuria and potential dehydration.

4. Important to maintain adequate hydration to prevent activation of V1 receptors.

Reference(s)

Wilkinson, I., Furmedge, D. and Sinharay, R. (2017). Oxford handbook of clinical medicine. Oxford: Oxford University Press. Get it on Amazon.
Feather, A., Randall, D. and Waterhouse, M. (2020). Kumar And Clark’s Clinical Medicine. 10th ed. S.L.: Elsevier Health Sciences. Get it on Amazon.
Hannaman, R. A., Bullock, L., Hatchell, C. A., & Yoffe, M. (2016). Internal medicine review core curriculum, 2017-2018. CO Springs, CO: MedStudy.
Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. https://www.tg.org.au [Accessed 2021].

@@ Line 10: / Line 10: @@
 ==Reference(s)==
-Wilkinson, I. (2017). Oxford handbook of clinical medicine. Oxford: Oxford University Press.
+Wilkinson, I., Furmedge, D. and Sinharay, R. (2017). Oxford handbook of clinical medicine. Oxford: Oxford University Press. [https://amzn.to/3YHrI6K Get it on Amazon.]
+<br/>Feather, A., Randall, D. and Waterhouse, M. (2020). Kumar And Clark’s Clinical Medicine. 10th ed. S.L.: Elsevier Health Sciences. [https://amzn.to/3k7WSW0 Get it on Amazon.]
 <br/>Hannaman, R. A., Bullock, L., Hatchell, C. A., & Yoffe, M. (2016). Internal medicine review core curriculum, 2017-2018. CO Springs, CO: MedStudy.
 <br/>Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. https://www.tg.org.au [Accessed 2021].